Prior to the development of panretinal photocoagulation (PRP) in the 1970s, proliferative diabetic retinopathy (PDR) was the most common cause of blindness in diabetic patients. The diabetic retinopathy study demonstrated that PRP could decrease severe visual loss from PDR by 50%. Since then and for the past four decades, PRP has been the treatment of choice for eyes with PDR. In the past decade, vascular endothelial growth factor (VEGF) inhibition has become the treatment of choice for diabetic macular edema (DME). When treated intensively with anti-VEGF drugs, about one-third of eyes with DME experience an improvement in their diabetic retinopathy severity scale. Randomized clinical trials comparing ranibizumab to PRP and aflibercept to PRP have shown that VEGF inhibitors cause regression of intraocular neovascularization but need to be given on a fairly regular basis. Despite these promising results, concerns about treatment adherence have surfaced. Patients with PDR that are treated solely with anti-VEGF drugs and somehow interrupt their treatment are at a high risk of developing irreversible blindness. Combination treatment of PRP plus an anti-VEGF drug may be the treatment of choice for PDR.
Keywords: Aflibercept; bevacizumab; diabetic retinopathy severity scale; intravitreal injection; panretinal photocoagulation; pattern scanning laser photocoagulation; proliferative diabetic retinopathy; ranibizumab; vascular endothelial growth factor.
Copyright: © 2019 Taiwan J Ophthalmol.
Conflict of interest statement
The authors declare that there are no conflicts of interests of this paper.
Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.Ophthalmology. 2017 Apr;124(4):431-439. doi: 10.1016/j.ophtha.2016.12.005. Epub 2017 Feb 1. Ophthalmology. 2017. PMID: 28161147 Free PMC article. Clinical Trial.
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.JAMA Ophthalmol. 2017 Jun 1;135(6):558-568. doi: 10.1001/jamaophthalmol.2017.0821. JAMA Ophthalmol. 2017. PMID: 28448655 Free PMC article. Clinical Trial.
The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.Drugs Context. 2018 Aug 13;7:212532. doi: 10.7573/dic.212532. eCollection 2018. Drugs Context. 2018. PMID: 30181760 Free PMC article. Review.
Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?Dev Ophthalmol. 2017;60:131-142. doi: 10.1159/000459699. Epub 2017 Apr 20. Dev Ophthalmol. 2017. PMID: 28427072 Review.
Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.JAMA Ophthalmol. 2017 Jun 1;135(6):576-584. doi: 10.1001/jamaophthalmol.2017.0837. JAMA Ophthalmol. 2017. PMID: 28492920 Free PMC article. Clinical Trial.
- Kalantzis G, Angelou M, Poulakou-Rebelakou E. Diabetic retinopathy: An historical assessment. Hormones (Athens) 2006;5:72–5. - PubMed
- Manz W. Retinitis proliferans. Graefes Arch Clin Exp Ophthalmol. 1876;22:229.
- Houssay BA, Biasotti A. Pancreatic diabetes in hypophysectomized dogs. Rev Soc Argent Biol. 1930;6:251.
- Poulsen JE. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes. 1953;2:7–12. - PubMed
- Kelly WF, Anapliotou M, Joplin GF. Pituitary ablation and its effect on diabetic retinopathy. Int Ophthalmol Clin. 1978;18:165–78. - PubMed